AbbVie, Harpoon Therapeutics in Immuno-Oncology Pact
AbbVie and Harpoon Therapeutics, a biotechnology company developing T-cell recruiting biologic therapies, have formed an immuno-oncology research collaboration.
The goal of the collaboration is to incorporate Harpoon’s tri-specific T-cell activating construct (TriTAC) platform with AbbVie’s research-stage immuno-oncology targets to develop cancer therapeutics.
Under the agreement, Harpoon will engineer TriTAC molecules directed against selected cancer targets using its proprietary platform, evaluate the molecules for pharmacologic properties, and provide AbbVie the right to pursue further development and commercialization of these molecules. Financial terms were not disclosed.